Advertisement

3D-porous β-tricalcium phosphate–alginate–gelatin scaffold with DMOG delivery promotes angiogenesis and bone formation in rat calvarial defects

  • Shahrbanoo Jahangir
  • Samaneh Hosseini
  • Farhad Mostafaei
  • Forough Azam Sayahpour
  • Mohamadreza Baghaban Eslaminejad
Tissue Engineering Constructs and Cell Substrates Original Research
  • 105 Downloads
Part of the following topical collections:
  1. Tissue Engineering Constructs and Cell Substrates

Abstract

Hypoxia-inducible factor-1α (HIF-1α), a well-studied angiogenesis pathway, plays an essential role in angiogenesis-osteogenesis coupling. Targeting the HIF-1a pathway frequently leads to successful reconstruction of large-sized bone defects through promotion of angiogenesis. Dimethyloxalylglycine (DMOG) small molecule regulates the stability of HIF-1α at normal oxygen tension by mimicking hypoxia, which subsequently accelerates angiogenesis. The current study aims to develop a novel construct by seeding adipose derived mesenchymal stem cells (ADMSCs) onto a scaffold that contains DMOG to induce angiogenesis and regeneration of a critical size calvarial defect in a rat model. The spongy scaffolds have been synthesized in the presence and absence of DMOG and analyzed in terms of morphology, porosity, pore size, mechanical properties and DMOG release profile. The effect of DMOG delivery on cellular behaviors of adhesion, viability, osteogenic differentiation, and angiogenesis were subsequently evaluated under in vitro conditions. Histological analysis of cell-scaffold constructs were also performed following transplantation into the calvarial defect. Physical characteristics of fabricated scaffolds confirmed higher mechanical strength and surface roughness of DMOG-loaded scaffolds. Scanning electron microscopy (SEM) images and MTT assay demonstrated the attachment and viability of ADMSCs in the presence of DMOG, respectively. Osteogenic activity of ADMSCs that included alkaline phosphatase (ALP) activity and calcium deposition significantly increased in the DMOG-loaded scaffold. Computed tomography (CT) imaging combined with histomorphometry and immunohistochemistry analysis showed enhanced bone formation and angiogenesis in the DMOG-loaded scaffolds. Therefore, spongy scaffolds that contained DMOG and had angiogenesis ability could be utilized to enhance bone regeneration of large-sized bone defects.

Notes

Acknowledgements

The present research was financially supported by Royan Institute for Stem Cell Biology and Technology. We thank Ms. Fatemeh Safari and Mr. Mohammad Hossein Ghanian for their help.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

10856_2018_6202_MOESM1_ESM.docx (4.1 mb)
Supplementary information

References

  1. 1.
    Arvidson K, Abdallah BM, Applegate LA, Baldini N, Cenni E, Gomez-Barrena E. et al. Bone regeneration and stem cells. J Cell Mol Med. 2011;15:718–46.  https://doi.org/10.1111/j.1582-4934.2010.01224.x.CrossRefGoogle Scholar
  2. 2.
    Khan SN, Cammisa FP Jr., Sandhu HS, Diwan AD, Girardi FP, Lane JM. The biology of bone grafting. J Am Acad Orthop Surg. 2005;13:77–86.CrossRefGoogle Scholar
  3. 3.
    Frohlich M, Grayson WL, Wan LQ, Marolt D, Drobnic M, Vunjak-Novakovic G. Tissue engineered bone grafts: biological requirements, tissue culture and clinical relevance. Curr Stem Cell Res Ther. 2008;3:254–64.CrossRefGoogle Scholar
  4. 4.
    Lokmic Z, Mitchell GM. Engineering the microcirculation. Tissue Eng Part B Rev. 2008;14:87–103.  https://doi.org/10.1089/teb.2007.0299.CrossRefGoogle Scholar
  5. 5.
    Kaigler D, Wang Z, Horger K, Mooney DJ, Krebsbach PH. VEGF scaffolds enhance angiogenesis and bone regeneration in irradiated osseous defects. J Bone Miner Res. 2006;21:735–44.  https://doi.org/10.1359/jbmr.060120.CrossRefGoogle Scholar
  6. 6.
    Khojasteh A, Fahimipour F, Eslaminejad MB, Jafarian M, Jahangir S, Bastami F. et al. Development of PLGA-coated beta-TCP scaffolds containing VEGF for bone tissue engineering. Mater Sci Eng C Mater Biol Appl. 2016;69:780–8.  https://doi.org/10.1016/j.msec.2016.07.011.CrossRefGoogle Scholar
  7. 7.
    Leach JK, Kaigler D, Wang Z, Krebsbach PH, Mooney DJ. Coating of VEGF-releasing scaffolds with bioactive glass for angiogenesis and bone regeneration. Biomaterials. 2006;27:3249–55.  https://doi.org/10.1016/j.biomaterials.2006.01.033.CrossRefGoogle Scholar
  8. 8.
    Chen RR, Silva EA, Yuen WW, Mooney DJ. Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm Res. 2007;24:258–64.  https://doi.org/10.1007/s11095-006-9173-4.CrossRefGoogle Scholar
  9. 9.
    Alsop AT, Pence JC, Weisgerber DW, Harley BAC, Bailey RC. Photopatterning of vascular endothelial growth factor within collagen-glycosaminoglycan scaffolds can induce a spatially confined response in human umbilical vein endothelial cells. Acta Biomater. 2014;10:4715–22.  https://doi.org/10.1016/j.actbio.2014.07.002.CrossRefGoogle Scholar
  10. 10.
    Fan L, Li J, Yu Z, Dang X, Wang K. The hypoxia-inducible factor pathway, prolyl hydroxylase domain protein inhibitors, and their roles in bone repair and regeneration. Biomed Res Int. 2014;2014:239356.  https://doi.org/10.1155/2014/239356.CrossRefGoogle Scholar
  11. 11.
    Wang Y, Wan C, Gilbert SR, Clemens TL. Oxygen sensing and osteogenesis. Ann N Y Acad Sci. 2007;1117:1–11.  https://doi.org/10.1196/annals.1402.049.CrossRefGoogle Scholar
  12. 12.
    Keith B, Johnson RS, Simon MCHIF1alpha. and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011;12:9–22.  https://doi.org/10.1038/nrc3183.CrossRefGoogle Scholar
  13. 13.
    Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393–410.  https://doi.org/10.1038/nrc3064.CrossRefGoogle Scholar
  14. 14.
    Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ. et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468–72.  https://doi.org/10.1126/science.1059796.CrossRefGoogle Scholar
  15. 15.
    Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 2003;22:4082–90.  https://doi.org/10.1093/emboj/cdg392.CrossRefGoogle Scholar
  16. 16.
    Mole DR, Schlemminger I, McNeill LA, Hewitson KS, Pugh CW, Ratcliffe PJ, et al. 2-oxoglutarate analogue inhibitors of HIF prolyl hydroxylase. Bioorg Med Chem Lett. 2003;13:2677–80.CrossRefGoogle Scholar
  17. 17.
    Holotnakova T, Ziegelhoffer A, Ohradanova A, Hulikova A, Novakova M, Kopacek J. et al. Induction of carbonic anhydrase IX by hypoxia and chemical disruption of oxygen sensing in rat fibroblasts and cardiomyocytes. Pflug Arch. 2008;456:323–37.  https://doi.org/10.1007/s00424-007-0400-6.CrossRefGoogle Scholar
  18. 18.
    Peng J, Lai ZG, Fang ZL, Xing S, Hui K, Hao C. et al.Dimethyloxalylglycine prevents bone loss in ovariectomized C57BL/6J mice through enhanced angiogenesis and osteogenesis. PLoS ONE. 2014;9:e112744.  https://doi.org/10.1371/journal.pone.0112744.CrossRefGoogle Scholar
  19. 19.
    Vogel S, Wottawa M, Farhat K, Zieseniss A, Schnelle M, Le-Huu S. et al.Prolyl hydroxylase domain (PHD) 2 affects cell migration and F-actin formation via RhoA/rho-associated kinase-dependent cofilin phosphorylation. J Biol Chem. 2010;285:33756–63. https://doi.org/10.1074/jbc.M110.132985.CrossRefGoogle Scholar
  20. 20.
    Qi X, Liu Y, Ding ZY, Cao JQ, Huang JH, Zhang JY. et al. Synergistic effects of dimethyloxallyl glycine and recombinant human bone morphogenetic protein-2 on repair of critical-sized bone defects in rats. Sci Rep. 2017;7:42820.  https://doi.org/10.1038/srep42820.CrossRefGoogle Scholar
  21. 21.
    Oryan A, Kamali A, Moshiri A, Baghaban Eslaminejad M. Role of mesenchymal stem cells in bone regenerative medicine: what is the evidence?. Cells Tissues Organs. 2017;204:59–83.  https://doi.org/10.1159/000469704.CrossRefGoogle Scholar
  22. 22.
    Fu WL, Xiang Z, Huang FG, Gu ZP, Yu XX, Cen SQ. et al.Coculture of peripheral blood-derived mesenchymal stem cells and endothelial progenitor cells on strontium-doped calcium polyphosphate scaffolds to generate vascularized engineered bone. Tissue Eng Part A. 2015;21:948–59. https://doi.org/10.1089/ten.TEA.2014.0267.CrossRefGoogle Scholar
  23. 23.
    Koob S, Torio-Padron N, Stark GB, Hannig C, Stankovic Z, Finkenzeller G. Bone formation and neovascularization mediated by mesenchymal stem cells and endothelial cells in critical-sized calvarial defects. Tissue Eng Part A. 2011;17:311–21.  https://doi.org/10.1089/ten.TEA.2010.0338.CrossRefGoogle Scholar
  24. 24.
    Strem BM, Hicok KC, Zhu M, Wulur I, Alfonso Z, Schreiber RE, et al. Multipotential differentiation of adipose tissue-derived stem cells. Keio J Med. 2005;54:132–41.CrossRefGoogle Scholar
  25. 25.
    Baer PC, Geiger H. Adipose-derived mesenchymal stromal/stem cells: tissue localization, characterization, and heterogeneity. Stem Cells Int. 2012;2012:812693.  https://doi.org/10.1155/2012/812693.CrossRefGoogle Scholar
  26. 26.
    Rennerfeldt DA, Van Vliet KJ. Concise review: when colonies are not clones: evidence and implications of intracolony heterogeneity in mesenchymal. Stem Cells. 2016;34:1135–41.  https://doi.org/10.1002/stem.2296.CrossRefGoogle Scholar
  27. 27.
    Eslaminejad MB, Mirzadeh H, Mohamadi Y, Nickmahzar A. Bone differentiation of marrow-derived mesenchymal stem cells using beta-tricalcium phosphate-alginate-gelatin hybrid scaffolds. J Tissue Eng Regen Med. 2007;1:417–24.  https://doi.org/10.1002/term.49.CrossRefGoogle Scholar
  28. 28.
    Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME. et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10:858–64.  https://doi.org/10.1038/nm1075.CrossRefGoogle Scholar
  29. 29.
    Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, Meijer GA. et al. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol. 2005;206:291–304.  https://doi.org/10.1002/path.1778.CrossRefGoogle Scholar
  30. 30.
    Kusumbe AP, Ramasamy SK, Adams RH. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature. 2014;507:323–8.  https://doi.org/10.1038/nature13145.CrossRefGoogle Scholar
  31. 31.
    Riddle RC, Khatri R, Schipani E, Clemens TL. Role of hypoxia-inducible factor-1alpha in angiogenic-osteogenic coupling. J Mol Med (Berl). 2009;87:583–90.  https://doi.org/10.1007/s00109-009-0477-9.CrossRefGoogle Scholar
  32. 32.
    Wan C, Shao J, Gilbert SR, Riddle RC, Long F, Johnson RS. et al. Role of HIF-1alpha in skeletal development. Ann N Y Acad Sci. 2010;1192:322–6.  https://doi.org/10.1111/j.1749-6632.2009.05238.x.CrossRefGoogle Scholar
  33. 33.
    Asikainen TM, Ahmad A, Schneider BK, Ho WB, Arend M, Brenner M. et al. Stimulation of HIF-1alpha, HIF-2alpha, and VEGF by prolyl 4-hydroxylase inhibition in human lung endothelial and epithelial cells. Free Radic Biol Med. 2005;38:1002–13.  https://doi.org/10.1016/j.freeradbiomed.2004.12.004.CrossRefGoogle Scholar
  34. 34.
    Ding H, Gao YS, Wang Y, Hu C, Sun Y, Zhang C. Dimethyloxaloylglycine increases the bone healing capacity of adipose-derived stem cells by promoting osteogenic differentiation and angiogenic potential. Stem Cells Dev. 2014;23:990–1000.  https://doi.org/10.1089/scd.2013.0486.CrossRefGoogle Scholar
  35. 35.
    Rey S, Lee K, Wang CJ, Gupta K, Chen S, McMillan A. et al. Synergistic effect of HIF-1alpha gene therapy and HIF-1-activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia. Proc Natl Acad Sci USA. 2009;106:20399–404.  https://doi.org/10.1073/pnas.0911921106.CrossRefGoogle Scholar
  36. 36.
    Tan R, Niu X, Gan S, Feng Q.Preparation and characterization of an injectable composite. J Mater Sci Mater Med. 2009;20:1245–53. https://doi.org/10.1007/s10856-009-3692-6.CrossRefGoogle Scholar
  37. 37.
    Wu C, Zhou Y, Chang J, Xiao Y. Delivery of dimethyloxallyl glycine in mesoporous bioactive glass scaffolds to improve angiogenesis and osteogenesis of human bone marrow stromal cells. Acta Biomater. 2013;9:9159–68.  https://doi.org/10.1016/j.actbio.2013.06.026.CrossRefGoogle Scholar
  38. 38.
    Aronson J. Temporal and spatial increases in blood flow during distraction osteogenesis. Clin Orthop Relat Res. 1994;301:124–31.Google Scholar
  39. 39.
    Mooney DJ, Mikos AG. Growing new organs. Sci Am. 1999;280:60–5.CrossRefGoogle Scholar
  40. 40.
    Yu H, VandeVord PJ, Mao L, Matthew HW, Wooley PH, Yang SY. Improved tissue-engineered bone regeneration by endothelial cell mediated vascularization. Biomaterials. 2009;30:508–17.  https://doi.org/10.1016/j.biomaterials.2008.09.047.CrossRefGoogle Scholar
  41. 41.
    Agis H, Hueber L, Pour Sadeghian N, Pensch M, Gruber R. In vitro release of dimethyloxaloylglycine and l-mimosine from bovine bone mineral. Arch Oral Biol. 2014;59:1024–31.  https://doi.org/10.1016/j.archoralbio.2014.05.027.CrossRefGoogle Scholar
  42. 42.
    Kim BS, Mooney DJ. Development of biocompatible synthetic extracellular matrices for tissue engineering. Trends Biotechnol. 1998;16:224–30.CrossRefGoogle Scholar
  43. 43.
    Min Z, Shichang Z, Chen X, Yufang Z, Changqing Z. 3D-printed dimethyloxallyl glycine delivery scaffolds to improve angiogenesis and osteogenesis. Biomater Sci. 2015;3:1236–44.  https://doi.org/10.1039/c5bm00132c.CrossRefGoogle Scholar
  44. 44.
    Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell. 2006;126:677–89.  https://doi.org/10.1016/j.cell.2006.06.044.CrossRefGoogle Scholar
  45. 45.
    Tokuda EY, Leight JL, Anseth KS. Modulation of matrix elasticity with PEG hydrogels to study melanoma drug responsiveness. Biomaterials. 2014;35:4310–8.  https://doi.org/10.1016/j.biomaterials.2014.01.063.CrossRefGoogle Scholar
  46. 46.
    Jaakkola P, Mole DR, Tian Y-M, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2- regulated prolyl hydroxylation. Science. 2001;292:468.CrossRefGoogle Scholar
  47. 47.
    Blum JS, Barry MA, Mikos AG, Jansen JA. In vivo evaluation of gene therapy vectors in ex vivo-derived marrow stromal cells for bone regeneration in a rat critical-size calvarial defect model. Hum Gene Ther. 2003;14:1689–701.  https://doi.org/10.1089/104303403322611719.CrossRefGoogle Scholar
  48. 48.
    Cowan CM, Aghaloo T, Chou YF, Walder B, Zhang X, Soo C. et al. MicroCT evaluation of three-dimensional mineralization in response to BMP-2 doses in vitro and in critical sized rat calvarial defects. Tissue Eng. 2007;13:501–12.  https://doi.org/10.1089/ten.2006.0141.CrossRefGoogle Scholar
  49. 49.
    Yoon E, Dhar S, Chun DE, Gharibjanian NA, Evans GR. In vivo osteogenic potential of human adipose-derived stem cells/poly lactide-co-glycolic acid constructs for bone regeneration in a rat critical-sized calvarial defect model. Tissue Eng. 2007;13:619–27.  https://doi.org/10.1089/ten.2006.0102.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Stem Cells and Developmental Biology, Cell Science Research CenterRoyan Institute for Stem Cell Biology and Technology, ACECRTehranIran
  2. 2.Department of Tissue engineering & Regenerative Medicine, Faculty of Advanced Technologies in MedicineIran University of Medical SciencesTehranIran
  3. 3.Animal Core Facility, Reproductive Biomedicine Research CenterRoyan Institute for Biotechnology, ACECRTehranIran

Personalised recommendations